Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation

Gilead Sciences Inc's GILD Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by lower Veklury (remdesivir) sales.

Product sales increased 7% to $6.6 billion, and excluding Veklury, product sales increased 11% to $6.3 billion.

HIV product sales increased 9% to $4.6 billion, with Biktarvy bringing in almost $3 billion.

The company reported adjusted EPS of $1.34, down 15% Y/Y, lagging the consensus of $1.61. The company said earnings were hurt by a $525 million, or $0.32 a share, charge related to HIV antitrust litigation settlements.

Also Read: Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer.

Guidance: Gilead revises FY23 sales guidance to $26.3 billion-$26.7 billion compared to previous guidance of $26-$26.5 billion versus the consensus of $26.66 billion. 

It forecasts adjusted EPS of $6.45-$6.80 versus the prior guidance of $6.60-$7.00 compared to consensus of $6.73.

Total product sales, excluding Veklury, are expected to be $24.6 billion-$25.0 billion, compared to $24.0 billion-$24.5 billion expected previously.

Total Veklury sales of approximately $1.7 billion, compared to approximately $2.0 billion expected previously.

Price Action: GILD shares are up 5.53% at $79.71 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareLegalMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!